UC 781

Drug Profile

UC 781

Alternative Names: UC-781

Latest Information Update: 24 Feb 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Uniroyal Chemical
  • Developer CONRAD
  • Class Amides; Antiretrovirals; Furans; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Feb 2009 Final pharmacodynamics and adverse events data from a phase I trial in HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009),
  • 01 Sep 2006 Discontinued - Preclinical for HIV infection prevention in Belgium (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top